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Abstract
Background Intra-articular injection of hyaluronic acid is
a well-established therapy for the treatment of knee
osteoarthritis. The aim of the study was to assess the
effectiveness and safety of the use of Arthrum HCS
(40 mg hyaluronic acid and 40 mg chondroitin sulfate in
2 mL).
Materials and methods This was an open, multicenter,
prospective study. Men or women over 40 years of age
with documented knee osteoarthritis and WOMAC sub-
score A (severity of pain) C25 were enrolled. They
received three weekly intra-articular injections of sodium
hyaluronate 2 % and chondroitin sulfate 2 % in combina-
tion. WOMAC subscore A was assessed at 1, 3 and
6 months after the last injection.
Results One hundred and twelve patients were included
(women, 66 %). The mean (SD) WOMAC subscore A
decreased from 52.1 (15.2) at inclusion to 20.5 (19.7) at
month 6 (P\ 0.0001). The mean subscore was already
significantly decreased 1 month after the last injection at
25.7 (P\ 0.0001). Pain relief and consumption of anal-
gesic drugs, both assessed with visual analogic scale
(VAS), consistently decreased. The investigators were
satisfied/very satisfied as regards the therapeutic effec-
tiveness of sodium hyaluronate-chondroitin sulfate in
reducing pain (77 %), improving mobility (78 %) and
reducing the consumption of analgesics (74 %). Only one
adverse effect was reported by one patient (knee
tumefaction).
Conclusion These results suggest that intra-articular
injections of Arthrum HCS (sodium hyaluronate plus
chondroitin sulfate) in patients with knee osteoarthritis are
efficient and safe. These results should be confirmed in a
randomized controlled study.
Level of evidence IV.
Keywords Knee osteoarthritis  Intra-articular injection 
Sodium hyaluronate  Chondroitin sulfate
Introduction
It is estimated that around 250 million people in the world
are affected by knee osteoarthritis [1]. Knee pain has an
important impact by limiting activity and impairing quality
of life. Thus, knee osteoarthritis has been identified as one
of the medical conditions (with stroke, depression, hip
fracture and heart disease) accounting for more physical
disability than other diseases in people 65 years of age or
older [2]. Moreover, knee osteoarthritis has a major impact
on healthcare costs [3–6].
The management of osteoarthritis should be hierarchi-
cal, with non pharmacological methods as first
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interventions (weight loss, exercise and braces), followed
by analgesic drugs [nonsteroidal anti-inflammatory drugs
(NSAIDs) and other analgesics], local therapies (topical
NSAIDs, intra-articular corticosteroids and hyaluronic
acid), and surgery as a last resort [7–10].
Administration of exogenous hyaluronic acid (visco-
supplementation) directly into the joint is available as a
treatment for the symptoms of knee osteoarthritis. The
purpose of viscosupplementation is to overcome the qual-
itative and quantitative deficiency of hyaluronic acid that is
associated with osteoarthritis. Hyaluronic acid is a
polysaccharide that is the main constituent of cartilage and
synovial fluid; it is responsible for the mechanical prop-
erties of the joint by allowing shock absorption, lubrication
and cartilage protection [11]. In osteoarthritis patients,
synovial hyaluronate is depolymerized and is cleared at
higher rates compared to normal subjects due to inflam-
mation [12]. Intra-articular injections of hyaluronic acid
have been shown to be as effective as NSAIDs with fewer
systemic adverse events [13]; this therapy has a delayed
onset of action in comparison with intra-articular corti-
costeroids, but a longer-lasting benefit [14]. Younger
patients and patients at an earlier stage of the disease are
more likely to benefit from viscosupplementation [15].
Arthrum HCS (LCA Pharmaceutical, Chartres, France)
is a new specialty for viscosupplementation combining
sodium hyaluronate and chondroitin sulfate. Chondroitin
sulfate—a sulfated glycosaminoglycan—is an important
structural component of the extracellular cartilage matrix.
On the articular system, chondroitin sulfate links to
monomers with high molecular weights. The proteoglycan
aggregate exhibits viscoelastic and hydration properties
and an ability to interact with the surrounding tissue
through electric charges, leading to protection of the car-
tilaginous tissues. Furthermore, chondroitin sulfates are
inhibitors of extracellular proteases involved in the meta-
bolism of connective tissues and stimulate proteoglycan
production by chondrocytes in vitro; they also inhibit car-
tilage cytokine production and induce apoptosis of articular
chondrocytes [16]. Preliminary clinical trials were in favor
of the effectiveness of intra-articular injections of sodium
hyaluronate-chondroitin sulfate. Thus, in a 3-month mul-
ticentric pilot study, a series of three weekly injections of a
combination of hyaluronic acid-chondroitin sulfate was
well tolerated and decreased pain in patients with knee
osteoarthritis [17]. A recent clinical study suggested that a
single injection of sodium hyaluronate-chondroitin sulfate
in patients with lateral epicondylitis offer better pain ben-
efits for 6 months after injection than intra-articular corti-
costeroids [18]. In an exploratory study, the effectiveness
of intra-articular injections of a solution combining hya-
luronic acid and chondroitin sulfate was assessed in 40
patients with knee osteoarthritis [19]. The clinical
improvement, together with the changes of the ultrasound
parameters and biomarkers of cartilage metabolism and
joint inflammation, suggested a non-placebo effect. These
results prompted us to assess in a prospective multicenter
study the effectiveness and safety of the use of hyaluronic




This was an open, multicenter, prospective study, assessing
the effectiveness of three intra-articular injections of
sodium hyaluronate plus chondroitin sulfate (40 mg of
each compound in 2 mL) in the symptomatic treatment of
knee osteoarthritis.
The study was conducted prospectively by office or
hospital specialists (orthopedic surgeons, rehabilitation
medicine physicians) from October 2012 to December
2013.
Written informed consent was obtained from each
patient. The protocol was conducted in accordance with the
Declaration of Helsinki and Guidelines on Good Clinical
Practice and approved by a local ethics committee.
Inclusion criteria
Men or women over 40 years of age were eligible to par-
ticipate if they: (1) had documented knee osteoarthritis
evidenced with X-rays over the past 6 months with Kell-
gren-Lawrence score grade II or III [20]; (2) had pain and
functional impairment for at least 3 months and Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) [21] subscore A (severity of pain) C25 (on a
scale of 100); and (3) needed hyaluronic acid injections
after the failure or intolerance to first-line analgesics or non
steroidal anti-inflammatory drugs. The main exclusion cri-
teria were: severe hydrarthrosis; inflammatory rheumatism;
history of knee trauma in the past 6 months; history of
arthroplasty or major surgery on the target knee in the past
6 months; history of arthroscopy or surgery on the target
knee in the past 3 months; planned knee surgery during the
study; history of septic arthritis of the knee; knee wound or
skin condition; crural or sciatic radiculalgia of the lower
limb; tendinopathy; symptomatic homolateral or contralat-
eral hip disease; venous or lymphatic stenosis of the lower
limb; medical history of venous thromboembolism (in-
cluding pulmonary embolism) or patient with high risk of
venous thromboembolism; patient with a history of auto-
immune disease; treatment with diacerein, avocado soy
unsaponifiables, glucosamine sulfate/chondroitin starting
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less than 3 months previously or with dosage modified
during the past 3 months; recurrent episodes of chondro-
calcinosis; previous treatment with viscosupplementation;
injection of corticosteroids into the knee under study less
than 3 months previously; known hypersensitivity to hya-
luronic acid or substances with similar activity; ongoing
anticoagulant therapy; pregnant or breastfeeding women.
Treatment and clinical assessments
Demographic, description and history of knee osteoarthri-
tis, concomitant treatments and WOMAC subscore A were
recorded at inclusion visit. The WOMAC (Western Ontario
and McMaster Universities) index is used to assess patients
with osteoarthritis of the hip or knee [21]. The subscore A
of the index is for pain assessment in five different cir-
cumstances: during walking (A1), using stairs (A2), in bed
(A3), sitting or lying (A4) and standing (A5). For each
item, pain is graded from 0 (none) to 100 (extreme). The
sum for the five items is divided by five to give WOMAC
subscore A.
Patients received three intra-articular injections of
Arthrum HCS (40 mg hyaluronic acid and 40 mg chon-
droitin sulfate in 2 mL) 1 week apart. Assessment of
treatment effectiveness and safety was performed during
follow-up visits at 1 month, 3 months and 6 months after
the last intra-articular injection.
The effectiveness assessment during the follow-up visits
included: WOMAC subscore A, relief of pain using a
visual analogic scale (VAS) ranging from 0 (‘‘maximum
relief’’, i.e., no pain) to 100 (‘‘no relief’’, i.e., maximal
pain) and consumption of analgesic drugs using a VAS
ranging from 0 (‘‘no consumption of analgesics’’) to 100
(‘‘maximal consumption of analgesics)’’.
Adverse events were recorded immediately after the
injections and during the follow-up visits.
Statistical analysis
Data from previous studies were used to estimate the
sample size [22, 23] With a loss to follow-up equal to
10 %, it was estimated that a sample size of 122 patients
would provide 50 % power to detect a significant change of
WOMAC subscore A (with alpha-risk at 5 %).
The primary endpoint was the change of WOMAC
subscore A from inclusion to end of study. The secondary
endpoints were the change of WOMAC subscore A from
inclusion to month 1 or month 3, relief of pain at months 1,
3 and 6, consumption of analgesic drugs from baseline to
months 1, 3 and 6 and global assessment by the investigator
at the end of the study for the three criteria: pain reduction,
improved mobility and consumption of analgesics.
Comparisons were made using Student’s t test for
quantitative criteria and Chi2 test for non-ordinal qualita-
tive variables (or Fisher’s exact test) and Wilcoxon’s test
for ordinal data. The threshold for significance was set at
5 %.
The analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC).
Results
Patient characteristics
Among 132 screened patients, 112 were analyzed (20
patients were \40 years of age and/or had a WOMAC
subscore A\25).
The characteristics of patients at inclusion are summa-
rized in Table 1. Two out of three patients were women
and the mean age was 65.4 years (range from 44 to
88 years). Two-thirds of patients had a body mass index
(BMI) above 25 kg/m2. The most frequent locations of
knee osteoarthritis were the medial compartment (34.8 %;
39/112), tricompartmental (32.2 %; 35/112), and patello-
Table 1 Characteristics of patients at inclusion
Characteristic N = 112
Age, years
Mean (SD) 65.4 (10.6)
Median (range) 66 (44–88)
Female gender, n (%) 74 (66.1)
Body mass indexa (kg/m2)





Study knee, n (%)
Right 67 (59.8 %)
Left 44 (3.3 %)
Right and left 1 (0.9 %)
Duration of knee osteoarthritisb, years, mean (SD) 3.0 (3.5)
Radiological stage, n (%)
Grade II 64 (57.1 %)
Grade III 48 (42.9 %)
Prior knee surgeryb n (%) 29 (27.9 %)
Prior physical medicine and rehabilitationc 48 (43.6 %)
At least one analgesic drug within 3 months 87 (77.7 %)
a Missing data for three patients
b Missing data for eight patients
c Missing data for two patients
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femoral/medial femoro-tibial (10.7 %; 12/112). Radiolog-
ical evaluation of osteoarthritis showed a Kellgren–Lawr-
ence stage 2 in 64 (57, 1 %) cases, and a Kellgren–
Lawrence stage 3 in 48 (42, 9 %) cases.
The mean duration of knee osteoarthritis was 3 years;
27.9 % (29/104) of patients underwent knee surgery (the
main operation was meniscectomy; 35.7 %, 10/28). The
median time between operation and inclusion was 7 years
(n = 28). Just under half of patients had benefited from
physical treatment and rehabilitation medicine (43.6 %;
48/110).
About four out of five patients (77.7 %; 87/112) were
taking at least one analgesic treatment during the 3 months
prior to the intra-articular injections: NSAIDs for 74.1 %
(83/112) of patients and an analgesic other than NSAIDs
for 34.9 % (38/109) of patients. There was a moderate
relief due to the analgesic treatment: on a VAS from 0 (no
relief) to 100 (maximal relief), the mean relief due to the
analgesic treatment was 50.8 and 53.9 according to the
investigator and the patient (n = 87), respectively.
Severity of pain—WOMAC subscore A
On inclusion, the mean WOMAC subscore A was 52.1
(range 26–86). At 6 months, the mean WOMAC subscore
A was 20.5 (range 0–80). Thus, the decrease of the sub-
score was -31.4 (P\ 0.0001; Wilcoxon signed rank test).
The change in the WOMAC subscore A during the study
is summarized in Fig. 1, and the changes in the five items
of WOMAC subscore A (A1, walking; A2, using stairs;
A3, in bed; A4, sitting or lying; A5, standing) are detailed
in Table 2. One month after the last injection, the mean
score decreased to 25.7 and pain continued to decrease
with a mean score of 20.4 at 3 months. This decrease in the
WOMAC subscore A at 1 month and 3 months was
statistically significant compared to baseline (Wilcoxon
signed rank test, P\ 0.0001).
Pain relief
One month after the last intra-articular injection, the mean
pain relief was assessed at 35.9 (25.6) on VAS by patients
(0, maximal pain relief; 100, no relief). Pain relief con-
tinued to decrease at 3 and 6 months: 28.1 (23.1) and 26.1
(25.4), respectively. Compared to the values at 1 month,
the values of pain relief at 3 and 6 months were statistically
significant (P\ 0.0001 and P = 0.0048, respectively).
Consumption of analgesic drugs
One month after the last intra-articular injection, the
patients assessed on a VAS their mean consumption of
analgesic drugs from 0 (no consumption of analgesics) to
100 (maximal consumption of analgesics). The mean (SD)
consumption decreased with time: 28.6 (24.4) at 1 month,
19.9 (21.7) at 3 months and 17.1 (22.3) at 6 months.
Compared to the values at 1 month, the scores of the
consumption of analgesic drugs at 3 and 6 months were
significantly decreased (P\ 0.0001 for both times).
Global assessment by investigators
The investigators were satisfied or very satisfied as regards
the therapeutic effectiveness of sodium hyaluronate-chon-
droitin sulfate in reducing pain (77 %), improving mobility
(78 %) and reducing the consumption of analgesics (74 %)
(Fig. 2).
Overall, about 80 % of investigators stated that the
results of the intra-articular injections of sodium hyalur-
onate-chondroitin sulfate combination were satisfactory or
very satisfactory.
Complications
One adverse effect was reported by one patient. This
adverse event was knee tumefaction, which lasted 3 days
after the first intra-articular injection.
Discussion
Viscosupplementation with hyaluronic acid alone has
demonstrated moderate but significant effectiveness vs
placebo in terms of pain and function in knee osteoarthritis
[11]. Our study is the first, to our knowledge, to assess the
effectiveness and safety of injections of Arthrum HCS in
a relatively large population of patients with knee
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* p < 0.0001 vs. baseline
Fig. 1 Pain severity (WOMAC subscore A) after three injections of
sodium hyaluronate-chondroitin sulfate in knee osteoarthritis
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assessed with the WOMAC subscore A decreased signifi-
cantly from 52.1 to 20.5 at 6 months. The relief was
already significant 1 month after the last injection. These
results were confirmed by the assessment of pain relief and
the decrease in the consumption of analgesics with VAS.
Approximately three out of four investigators were satis-
fied/very satisfied as regards to the therapeutic effective-
ness of the injections of sodium hyaluronate-chondroitin
sulfate in reducing pain, improving mobility and reducing
the consumption of analgesics.
The pilot study of Maheu et al. [17] in 41 patients with
femoro-tibial knee osteoarthritis also reported an
improvement 3 months after three 2-mL injections of
hyaluronic acid (12 mg/mL) plus chondroitin sulfate
(30 mg/mL). The mean VAS score decreased from 61 at
baseline to 29 after 3 months (60 % of patients reported an
improvement above 50 %). Although the dosages of the
compounds were slightly different, these results are con-
sistent with those of the present study.
The very low proportion of patients with adverse events
confirms the safety of viscosupplementation in knee
osteoarthritis. The harmlessness of viscosupplementation
in knee osteoarthritis has been confirmed in a recent
systematic review and meta-analysis of randomized saline-
controlled trials for US-approved intra-articular hyaluronic
acid [24]. There were no statistically significant differences
between hyaluronic acid and saline controls for any safety
outcome.
It is now debated that surgical procedures in knee
osteoarthritis should be avoided as far as possible or at
least delayed [25, 26]. The restoration of the viscoelas-
ticity of the synovial fluid in order to protect cartilage, if
possible during the early states of the disease, is an
attractive therapeutic option. Moreover, a medico-eco-
nomic evaluation showed that, together with clinical
benefits, costs of knee osteoarthritis decreased after
hyaluronic acid injections due to the decreased need for
other treatments [23]. However no therapies have been
shown to alter the natural history of osteoarthritis. In the
absence of disease modifying osteoarthritis drugs,
treatment of osteoarthritis is focused on controlling
symptoms, especially pain [10, 27, 28]. Until prospective
studies on the efficacy of hyaluronic acid on knee
arthroplasty delay are completed, intra-articular treat-
ment must be considered an additional non-operative
strategy for relief of symptoms.
There are some limitations of the study. First, there was
no control group. Indeed, there is a debate on the effec-
tiveness of viscosupplementation in osteoarthritis, but
some meta-analyses found an advantage of viscosupple-
mentation over sham intervention [14, 24, 25]. Therefore, it
was difficult to justify a sham control in one group. Nev-
ertheless, the kinetics of the effect observed in the present
study conform to the conclusions of a meta-analysis on
viscosupplementation that showed that effectiveness
became significant at 4 weeks, peaked at 8 weeks and
persisted for 6 months [14]. Another limitation was the
absence of demonstration of the benefit of the addition of
chondroitin sulfate to hyaluronic acid. With a comparable
total number of patients, the statistical power of the trial
would decrease with an additional treatment group (hya-
luronic acid alone). This issue should certainly be addres-
sed in further studies.
Table 2 Pain severity
(WOMAC subscore A) after
three intra-articular injections of
sodium hyaluronate-chondroitin
sulfate. Results are given as
mean (SD). For each item, pain
is graded from 0 (none) to 100
(extreme)
Time (months) 0 1 3 6
N 112 111 111 109
Items of WOMAC A
A1 (walking) 46.0 (22.2) 23.3 (19.8) 17.7 (18.3) 16.7 (20.3)
A2 (using stairs) 72.1 (17.3) 37.0 (22.9) 31.0 (22.8) 31.0 (26.7)
A3 (in bed) 34.9 (25.2) 15.5 (19.0) 10.9 (17.7) 10.6 (18.0)
A4 (sitting or lying) 60.6 (21.4) 30.1 (21.7) 24.6 (19.4) 25.4 (23.8)
A5 (standing) 46.8 (23.5) 22.4 (22.5) 17.7 (18.8) 18.8 (22.2)
WOMAC A 52.1 (15.2)a 25.7 (17.4)a 20.4 (16.3)a 20.5 (19.7)a
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Inadequate Moderate Satisfactory Very satisfactory
Fig. 2 Overall assessment of efficacy of three injections of sodium
hyaluronate-chondroitin sulfate in knee osteoarthritis by the
investigator
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Arthrum HCS is a new intra-articular treatment com-
bining in the same injection two compounds that are defi-
cient in osteoarthritis. Chondroitin sulfate is an essential
component of cartilage and is present also in synovial fluid.
Our results suggest that intra-articular injections of
Arthrum HCS (sodium hyaluronate plus chondroitin sul-
fate) in patients with knee osteoarthritis allows a safe and
effective control of pain. These results should be confirmed
in a randomized controlled study.
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